Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00039416 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)